Literature DB >> 15952966

Hair loss with chemotherapy: at a loss over its management?

J Randall1, E Ream.   

Abstract

Alopecia is a common side effect of chemotherapy treatments for cancer; for some individuals this results in complete hair loss. The extent of this depends on many factors including the type or combination of drugs administered, and their doses. Further, it can in some cases be lessened through use of scalp cooling techniques. This method of reducing hair loss has been available since the 1970s. However, previous evidence suggests that nurses are apathetic about its use, which in turn might mean that patients are not always offered this intervention. This small exploratory study investigated perceptions held by nurses administering chemotherapy towards alopecia and its management through scalp cooling. It entailed completion of a survey questionnaire by 13 nurses that regularly administered intravenous chemotherapy. These data were then augmented by those attained from follow-up, semi-structured interviews that were conducted with three of the sample. It determined that perceptions of scalp cooling were influenced by individuals' subjective notions of its efficacy constructed from their experiences of having administered scalp cooling. Furthermore, attempts to prevent hair loss were mediated by their cognitions of the experience of hair loss itself. This study determined that views held about scalp cooling varied considerably, and that it was unlikely to be offered to all suitable patients or administered in a systematic manner. Such variation in provision has implications both for patients wishing to access this treatment and for nurses wishing to audit its use and efficacy.

Entities:  

Mesh:

Year:  2005        PMID: 15952966     DOI: 10.1111/j.1365-2354.2005.00558.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  2 in total

1.  Effects of alopecia on body image and quality of life of Turkish cancer women with or without headscarf.

Authors:  Ozgul Erol; Gulbeyaz Can; Adnan Aydıner
Journal:  Support Care Cancer       Date:  2011-12-17       Impact factor: 3.603

2.  Identification of oxidized protein hydrolase as a potential prodrug target in prostate cancer.

Authors:  Christopher A McGoldrick; Yu-Lin Jiang; Victor Paromov; Marianne Brannon; Koyamangalath Krishnan; William L Stone
Journal:  BMC Cancer       Date:  2014-02-10       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.